Annotation_id
stringclasses 3
values | Claim_topic_id
stringclasses 516
values | Evidence_topic_id
stringlengths 21
35
| Claim_text
stringclasses 590
values | Label
stringclasses 3
values | Evidence Label
stringclasses 3
values | Evidence_text
stringlengths 12
794
⌀ | Article_topic_id
stringclasses 560
values | Reason
stringclasses 307
values |
|---|---|---|---|---|---|---|---|---|
B_2.0 | Claims_Climate_B2.0_51 | Evidence_Climate_B2.0_301 | The paris agreement was signed in 2022 | F | F | South Africa updated its NDC under the Paris Agreement in 2021 and now has a proposed revised target range of 398 to 510 Mt CO2-eq for 2025, and 398 to 440 Mt CO2-eq for 2030. | Emission trading scheme_9428 | In 2015, 190 countries signed up to the Paris Agreement and set emissions reduction targets. |
B_2.0 | Claims_Climate_B2.0_51 | Evidence_Climate_B2.0_302 | The paris agreement was signed in 2023 | F | F | In 2015, 190 countries signed up to the Paris Agreement and set emissions reduction targets. | Emission trading scheme_9507 | null |
B_2.0 | Claims_Climate_B2.0_51 | Evidence_Climate_B2.0_303 | The paris agreement was signed in 2024 | F | F | When it was concluded in 2015, the Paris Agreement recognised, under its Article 6, several different modes of international cooperation for countries to implement their national climate commitments, including two proposed new carbon markets. | Emission trading scheme_9564 | null |
B_2.0 | Claims_Climate_B2.0_51 | Evidence_Climate_B2.0_304 | The paris agreement was signed in 2025 | F | N | This option is not currently available under the Paris Agreement. | Emission trading scheme_9515 | null |
B_2.0 | Claims_Climate_B2.0_51 | Evidence_Climate_B2.0_305 | The paris agreement was signed in 2026 | F | N | The recent U.N. Climate Change Conference of the Parties, or COP26,accelerated action this decade to achieve deeper reductions in greenhouse gas emissions, nationally determined contributions for 2030 aligned with the Paris Agreement goal to limit global warming to 1.5 degrees Celsius above preindustrial levelsand to phase down coal power. | Emission trading scheme_9536 | null |
B_2.0 | Claims_Climate_B2.0_51 | Evidence_Climate_B2.0_306 | The paris agreement was signed in 2027 | F | N | This analysis may reveal the companies that could sustain greater fiscal damage than others if Chinese policymakers implement a tax scheme similar to the one being used in Europe. | Emission trading scheme_9571 | null |
B_2.0 | Claims_Climate_B2.0_52 | Evidence_Climate_B2.0_307 | The EU ETS covers 36% of the EU's total greenhouse gas emissions. | F | T | The EU ETS covers about 36% of the EU's total greenhouse gas emissions. | Emission trading scheme_9431 | While the EU ETS does cover a significant amount of total green house gas emissions the estimated amount varies depending on the source of information |
B_2.0 | Claims_Climate_B2.0_52 | Evidence_Climate_B2.0_308 | The EU ETS covers 36% of the EU's total greenhouse gas emissions. | F | F | The sectors covered by the EU ETS today account for 41% of the EU's total emissions. | Emission trading scheme_9501 | null |
B_2.0 | Claims_Climate_B2.0_52 | Evidence_Climate_B2.0_309 | The EU ETS covers 36% of the EU's total greenhouse gas emissions. | F | N | The programme aims to cut 17 percent of total emissions required in the next three years, and about a third of emissions reductions required by the end of the decade. | Emission trading scheme_9543 | null |
B_2.0 | Claims_Climate_B2.0_52 | Evidence_Climate_B2.0_310 | The EU ETS covers 36% of the EU's total greenhouse gas emissions. | F | N | They must have enough allowances to cover their total emissions for each year or they are subject to heavy fines. | Emission trading scheme_9544 | null |
B_2.0 | Claims_Climate_B2.0_52 | Evidence_Climate_B2.0_311 | The EU ETS covers 36% of the EU's total greenhouse gas emissions. | F | F | Carbon credits will continue to gain in importance because demand is outstripping supply, with more and more companies interested in offsetting their emissionsOne of the most demanding compliance markets is the European Union's Emissions Trading Scheme (ETS), which is made up of some 10,000 companies responsible for 40% of total emissions in the region. | Emission trading scheme_9564 | null |
B_2.0 | Claims_Climate_B2.0_52 | Evidence_Climate_B2.0_312 | The EU ETS covers 36% of the EU's total greenhouse gas emissions. | F | N | The impact of climate policies in terms of government budget revenuea) Environmental taxes and EU emissions trading system revenues in the euro area(percentages of total public revenues)b) Revenues from national carbon taxes and emissions trading schemes by country(carbon tax rate in EUR per tonne of CO2 equivalent greenhouse gas emissions; emissions covered as percentages of total emissions)Sources: Eurostat, World Bank and own calculations. | Emission trading scheme_9754 | null |
B_2.0 | Claims_Climate_B2.0_53 | Evidence_Climate_B2.0_313 | The european commision plans to raise 20 billion from the EU's carbon market | T | N | The national carbon market celebrated its first anniversary in July and has now replaced the European Union Emissions Trading System the EU ETS as the world's largest carbon trading system by coverage, including over 2,000 companies in the power sector and involving more than 4.5 billion metric tons of carbon dioxide per year, said China's Ministry of Ecology and Environment. | Emission trading scheme_9765 | The European Commission published plans in May to end the EU\'s reliance on Russian gas this decade, including a proposal to raise 20 billion euros ($20 billion) by allowing countries to sell carbon permits stored in the Emission Trading Scheme\'s (ETS) "market stability reserve". |
B_2.0 | Claims_Climate_B2.0_53 | Evidence_Climate_B2.0_314 | The european commision plans to raise 20 billion from the EU's carbon market | T | T | We will bring 20 billion of grant money from the auction of allowances from the market stability reserve, said a senior EU official who briefed the press yesterday about the Commission's plans. | Emission trading scheme_9433 | null |
B_2.0 | Claims_Climate_B2.0_53 | Evidence_Climate_B2.0_315 | The european commision plans to raise 20 billion from the EU's carbon market | T | N | Key European lawmakers in an interim vote late on Monday stuck to a compromise that would part-finance the REPowerEU strategy with 20 billion worth of carbon allowance sales solely sourced from frontloaded member state auctions over three years. | Emission trading scheme_9734 | null |
B_2.0 | Claims_Climate_B2.0_53 | Evidence_Climate_B2.0_316 | The european commision plans to raise 20 billion from the EU's carbon market | T | T | Analysts have slammed European Commission plans to raise 20 billion from the EU's carbon market stability reserve as a way of financing a 300-billion effort to wean Europe off Russian fossil fuels. | Emission trading scheme_9433 | null |
B_2.0 | Claims_Climate_B2.0_53 | Evidence_Climate_B2.0_317 | The european commision plans to raise 20 billion from the EU's carbon market | T | T | The European Commission published plans in May to end the EU\'s reliance on Russian gas this decade, including a proposal to raise 20 billion euros ($20 billion) by allowing countries to sell carbon permits stored in the Emission Trading Scheme\'s (ETS) "market stability reserve". | Emission trading scheme_9450 | null |
B_2.0 | Claims_Climate_B2.0_53 | Evidence_Climate_B2.0_318 | The european commision plans to raise 20 billion from the EU's carbon market | T | N | Janusz Kowalski, an MP with the right-wing United Poland party a junior member of the nationalist ruling coalition last week attacked the ETS for "this year pulling 20 billion z_oty (4.3 billion) from the state budget. | Emission trading scheme_9699 | null |
B_2.0 | Claims_Climate_B2.0_54 | Evidence_Climate_B2.0_319 | The european commision plans to raise 15 billion from the EU's carbon market | F | F | Analysts have slammed European Commission plans to raise 20 billion from the EU's carbon market stability reserve as a way of financing a 300-billion effort to wean Europe off Russian fossil fuels. | Emission trading scheme_9433 | The European Commission published plans in May to end the EU\'s reliance on Russian gas this decade, including a proposal to raise 20 billion euros ($20 billion) by allowing countries to sell carbon permits stored in the Emission Trading Scheme\'s (ETS) "market stability reserve". |
B_2.0 | Claims_Climate_B2.0_54 | Evidence_Climate_B2.0_320 | The european commision plans to raise 15 billion from the EU's carbon market | F | F | The European Commission published plans in May to end the EU\'s reliance on Russian gas this decade, including a proposal to raise 20 billion euros ($20 billion) by allowing countries to sell carbon permits stored in the Emission Trading Scheme\'s (ETS) "market stability reserve". | Emission trading scheme_9450 | null |
B_2.0 | Claims_Climate_B2.0_54 | Evidence_Climate_B2.0_321 | The european commision plans to raise 15 billion from the EU's carbon market | F | N | Janusz Kowalski, an MP with the right-wing United Poland party a junior member of the nationalist ruling coalition last week attacked the ETS for "this year pulling 20 billion z_oty (4.3 billion) from the state budget. | Emission trading scheme_9699 | null |
B_2.0 | Claims_Climate_B2.0_54 | Evidence_Climate_B2.0_322 | The european commision plans to raise 15 billion from the EU's carbon market | F | N | According to consultancy McKinsey, USD 1 billion was estimated to have been spent on offsets in 2021 and the market could expand to USD 15 billion 2030 and USD 100 billion by 2050. | Emission trading scheme_9936 | null |
B_2.0 | Claims_Climate_B2.0_54 | Evidence_Climate_B2.0_323 | The european commision plans to raise 15 billion from the EU's carbon market | F | N | This will raise the value of carbon credits futures and this asset class will likely benefit significantly over the longer term, making it attractive for investors to get exposure. | Emission trading scheme_9942 | null |
B_2.0 | Claims_Climate_B2.0_54 | Evidence_Climate_B2.0_324 | The european commision plans to raise 15 billion from the EU's carbon market | F | F | Raising the 20 billion for REPowerEU by taking allowances currently sitting in the EU ETS's Market Stability Reserve (MSR) would increase the supply of allowances on the market and reduce the CO2 price, therefore rendering a one-off reduction of the cap even more necessary. | Emission trading scheme_9411 | null |
B_2.0 | Claims_Covid_B2.0_55 | Evidence_Covid_B2.0_1 | Covid Vaccine Safe for Children | T | null | vaccines are generally very safe, and that extending the interval between Doses 1 and 2 minimises the risk of vaccine-induced myocarditis | covid vaccine_4074 | Trials and data give confidence that vaccines are safe for children |
B_2.0 | Claims_Covid_B2.0_55 | Evidence_Covid_B2.0_2 | Covid Vaccine Safe for Children | T | null | evidence from trials and real-world data from children in this age bracket receiving the vaccines, gives us the confidence in the safety of this vaccine | covid vaccine_4074 | null |
B_2.0 | Claims_Covid_B2.0_55 | Evidence_Covid_B2.0_3 | Covid Vaccine Safe for Children | T | null | “These boosters have been proven safe and effective for adults and children. If you have been thinking about getting the vaccine, now is the time.” | covid vaccine_4132 | null |
B_2.0 | Claims_Covid_B2.0_55 | Evidence_Covid_B2.0_4 | Covid Vaccine Safe for Children | T | null | The health ministry on Oct. 5 approved two vaccines for COVID-19, including the first to be made available for children under 4. | covid vaccine_4199 | null |
B_2.0 | Claims_Covid_B2.0_55 | Evidence_Covid_B2.0_5 | Covid Vaccine Safe for Children | T | null | Studies have also looked at side effects in infants between the ages of 6 months and 2 years. Fevers of 38 degrees or higher were recorded after the booster shot in 6.8 percent of the cases. One report stated 20.2 percent of the infants lost their appetite. There were no reports of death. | covid vaccine_4199 | null |
B_2.0 | Claims_Covid_B2.0_55 | Evidence_Covid_B2.0_6 | Covid Vaccine Safe for Children | T | null | The new vaccine was approved because there are likely to be almost no safety concerns since only slight changes were made to the substance used in the vaccine against the BA.1 subvariant. | covid vaccine_4199 | null |
B_2.0 | Claims_Covid_B2.0_56 | Evidence_Covid_B2.0_7 | Pfizer did not test Covid vaccine before its release | F | null | Fact Check found this to be a misinterpretation of remarks made by a Pfizer executive | covid vaccine_4076 | Vaccine was evaluated via Clinical trials |
B_2.0 | Claims_Covid_B2.0_56 | Evidence_Covid_B2.0_8 | Pfizer did not test Covid vaccine before its release | F | null | The vaccine was evaluated to determine whether or not it protects symptomatic Covid-19 | covid vaccine_4076 | null |
B_2.0 | Claims_Covid_B2.0_56 | Evidence_Covid_B2.0_9 | Pfizer did not test Covid vaccine before its release | F | null | clinical trials were focused on determining the jab's efficacy in preventing severe Covid-19 disease | covid vaccine_4076 | null |
B_2.0 | Claims_Covid_B2.0_56 | Evidence_Covid_B2.0_10 | Pfizer did not test Covid vaccine before its release | F | null | Pfizer-BioNTech vaccine went through three phases of clinical trials | covid vaccine_4076 | null |
B_2.0 | Claims_Covid_B2.0_56 | Evidence_Covid_B2.0_11 | Pfizer did not test Covid vaccine before its release | F | null | Pfizer's large-scale clinical trial carried out on thousands of volunteers | covid vaccine_4076 | null |
B_2.0 | Claims_Covid_B2.0_56 | Evidence_Covid_B2.0_12 | Pfizer did not test Covid vaccine before its release | F | null | Results of phase III Pfizer-BioNTech vaccine clinical trials released by the US Food and Drug Administration (FDA) on December 10, 2020, | covid vaccine_4076 | null |
B_2.0 | Claims_Covid_B2.0_57 | Evidence_Covid_B2.0_13 | Full vaccination more effective than boosters in preventing spread of COVID-19 | T | null | A small increase in the number of people having two vaccines against COVID-19 was more effective in controlling the virus during Europe's fourth wave—when the omicron variant appeared—than the rapid uptake of booster vaccines, finds a new UCL-led study | covid vaccine_4078 | UCL study found full vaccines to be more effective than boosters |
B_2.0 | Claims_Covid_B2.0_57 | Evidence_Covid_B2.0_14 | Full vaccination more effective than boosters in preventing spread of COVID-19 | T | null | Published in the International Journal of Public Health, the study found that a 4.2% increase in the number of people having two doses (full vaccination) led to a 54% reduction in case rates across Europe—despite the detection of the highly infectious omicron | covid vaccine_4078 | null |
B_2.0 | Claims_Covid_B2.0_57 | Evidence_Covid_B2.0_15 | Full vaccination more effective than boosters in preventing spread of COVID-19 | T | null | The results found that a small increase in full vaccination coverage prevented many COVID-19 cases over the last few months of 2021, across Europe. | covid vaccine_4078 | null |
B_2.0 | Claims_Covid_B2.0_57 | Evidence_Covid_B2.0_16 | Full vaccination more effective than boosters in preventing spread of COVID-19 | T | null | We know vaccines work and they offer the best protection from becoming seriously ill and requiring hospital treatment | covid vaccine_4084 | null |
B_2.0 | Claims_Covid_B2.0_57 | Evidence_Covid_B2.0_17 | Full vaccination more effective than boosters in preventing spread of COVID-19 | T | null | The Pfizer-BioNTech COVID-19 vaccine limits transmission, hospitalization, and death from COVID-19 even among patients infected by variants of the virus | covid vaccine_4163 | null |
B_2.0 | Claims_Covid_B2.0_57 | Evidence_Covid_B2.0_18 | Full vaccination more effective than boosters in preventing spread of COVID-19 | T | null | emergence of new variants, including Delta and Omicron, left the vaccine less effective at neutralizing SARS-CoV-2 | covid vaccine_4163 | null |
B_2.0 | Claims_Covid_B2.0_58 | Evidence_Covid_B2.0_19 | Covid Vaccines effective against severe illness | T | null | Dr. Jain added, "Vaccines are thought to be effective in preventing severe illness with COVID-19 but less effective in preventing symptomatic disease with the omicron variant." | covid vaccine_4078 | Many places say that vaccines are effective in preventing severe illness |
B_2.0 | Claims_Covid_B2.0_58 | Evidence_Covid_B2.0_20 | Covid Vaccines effective against severe illness | T | null | Current vaccines against SARS-CoV-2 substantially reduce mortality and severe disease, but protection against infection is less effective. | covid vaccine_4079 | null |
B_2.0 | Claims_Covid_B2.0_58 | Evidence_Covid_B2.0_21 | Covid Vaccines effective against severe illness | T | null | “Also, it’s important to remember that if you get vaccinated for flu and COVID and still contract either virus, you’re much less likely to have a severe illness than someone who is unvaccinated,” Hartford said | covid vaccine_4081 | null |
B_2.0 | Claims_Covid_B2.0_58 | Evidence_Covid_B2.0_22 | Covid Vaccines effective against severe illness | T | null | Current vaccines against SARS-CoV-2 substantially reduce mortality and severe disease, but protection against infection is less effective. Vaccinated individuals are still catching COVID-19 and can spread the infection, so breakthrough infections are still occurring," said Dr Ashhurst. | covid vaccine_4083 | null |
B_2.0 | Claims_Covid_B2.0_58 | Evidence_Covid_B2.0_23 | Covid Vaccines effective against severe illness | T | null | An official said at a press conference that vaccination is still effective in preventing severe illness and death | covid vaccine_4140 | null |
B_2.0 | Claims_Covid_B2.0_58 | Evidence_Covid_B2.0_24 | Covid Vaccines effective against severe illness | T | null | According to the World Health Organization, Covid-19 vaccines are "highly effective" in preventing serious illness, hospitalisation and death, | covid vaccine_4158 | null |
B_2.0 | Claims_Covid_B2.0_59 | Evidence_Covid_B2.0_25 | Nasal vaccine strategy could prevent covid-19 transmission | T | null | Researchers from the Centenary Institute and the University of Sydney have developed a new nasal vaccination strategy that induces potent lung immunity and protection against the SARS-CoV-2 coronavirus | covid vaccine_4079 | Nasal Vaccine strategy successful in stopping transmission of Covid-19 in mice |
B_2.0 | Claims_Covid_B2.0_59 | Evidence_Covid_B2.0_26 | Nasal vaccine strategy could prevent covid-19 transmission | T | null | "Our vaccine differs from most current COVID-19 vaccines in that it enables generation of an immune response directly in those areas of the body that are likely to be the first point of contact for the virus - the nose, airway and lungs. This may help explain the vaccine's effectiveness," said Dr Ashhurst. | covid vaccine_4083 | null |
B_2.0 | Claims_Covid_B2.0_59 | Evidence_Covid_B2.0_27 | Nasal vaccine strategy could prevent covid-19 transmission | T | null | "To stop viral spread and to prevent this virus from mutating we need a new vaccine approach that blocks COVID-19 transmission," she said. | covid vaccine_4079 | null |
B_2.0 | Claims_Covid_B2.0_59 | Evidence_Covid_B2.0_28 | Nasal vaccine strategy could prevent covid-19 transmission | T | null | Significantly, none of the vaccinated mice became infected with COVID-19. | covid vaccine_4079 | null |
B_2.0 | Claims_Covid_B2.0_59 | Evidence_Covid_B2.0_29 | Nasal vaccine strategy could prevent covid-19 transmission | T | null | "Our vaccine differs from most current COVID-19 vaccines in that it enables generation of an immune response directly in those areas of the body that are likely to be the first point of contact for the virus—the nose, airway and lungs. This may help explain the vaccine's effectiveness," said Dr. Ashhurst | covid vaccine_4079 | null |
B_2.0 | Claims_Covid_B2.0_59 | Evidence_Covid_B2.0_30 | Nasal vaccine strategy could prevent covid-19 transmission | T | null | "Our vaccination findings have shown exciting potential in pre-clinical studies, improving protection against SARS-CoV-2 infection. The approach developed here could help break the COVID-19 infection cycle and will likely influence future coronavirus vaccine related studies," Professor Britton said. | covid vaccine_4079 | null |
B_2.0 | Claims_Covid_B2.0_60 | Evidence_Covid_B2.0_31 | Staying up to date with booster vaccines best protection against infection | T | null | Until the development of long-lasting, “universal” coronavirus vaccines, our best strategy for protection against infection, hospitalization and death is staying up to date with our booster shots. | covid vaccine_4085 | Best strategy for protection against infection is newer booster shots. |
B_2.0 | Claims_Covid_B2.0_60 | Evidence_Covid_B2.0_32 | Staying up to date with booster vaccines best protection against infection | T | null | In addition, the newer booster vaccines provide significant additional protection against infection in seniors when compared to the original vaccines alone, according to investigators with the Centers for Disease Control and Prevention. | covid vaccine_4145 | null |
B_2.0 | Claims_Covid_B2.0_60 | Evidence_Covid_B2.0_33 | Staying up to date with booster vaccines best protection against infection | T | null | For those aged 50 to 64 years, protection derived from the bivalent booster dose compared to monovalent vaccines rose from 31% at two to three months after receipt of the most recent monovalent dose to 48% at eight months. | covid vaccine_4145 | null |
B_2.0 | Claims_Covid_B2.0_60 | Evidence_Covid_B2.0_34 | Staying up to date with booster vaccines best protection against infection | T | null | The relative increase in protection from the bivalent vaccines is likely due to the waning of the monovalent vaccines’ effectiveness over time, wrote Tamara Pilishvili, PhD, of the CDC’s National Center for Immunization and Respiratory Diseases. | covid vaccine_4145 | null |
B_2.0 | Claims_Covid_B2.0_60 | Evidence_Covid_B2.0_35 | Staying up to date with booster vaccines best protection against infection | T | null | “All persons should stay up-to-date with recommended COVID-19 vaccines, including bivalent booster doses, if it has been two or more months since their last monovalent vaccine dose,” she and her colleagues concluded. | covid vaccine_4145 | null |
B_2.0 | Claims_Covid_B2.0_60 | Evidence_Covid_B2.0_36 | Staying up to date with booster vaccines best protection against infection | T | null | The updated, bivalent vaccine is currently the preferred booster. | covid vaccine_4145 | null |
B_2.0 | Claims_Covid_B2.0_61 | Evidence_Covid_B2.0_37 | COVID-19 Vaccine Causes Shingles | F | null | No association was detected between COVID-19 vaccination and herpes zoster infection in a database study involving more than 2 million individuals in the U.S. | covid vaccine_4090 | No increase in herpes zoster (shingles) after vaccination |
B_2.0 | Claims_Covid_B2.0_61 | Evidence_Covid_B2.0_38 | COVID-19 Vaccine Causes Shingles | F | null | Using a self-controlled risk interval (SCRI) analysis, the risk of herpes zoster in the month after receiving a dose of COVID-19 vaccine was no different when compared with a control period 60 to 90 days following an individuals' last dose (incidence rate ratio [IRR] 0.91, 95% CI 0.82-1.01, P=0.08), reported Nisha Acharya, MD, MS, of the University of California San Francisco, and colleagues. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_61 | Evidence_Covid_B2.0_39 | COVID-19 Vaccine Causes Shingles | F | null | "There was no increase in risk of herpes zoster after COVID-19 vaccination when individuals were stratified by age, immunocompromised status, or type of vaccine administered," the group wrote in JAMA Network Openopens in a new tab or window. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_61 | Evidence_Covid_B2.0_40 | COVID-19 Vaccine Causes Shingles | F | null | For example, an international matched cohort studyopens in a new tab or window involving more than 1 million vaccinated individuals detected a nearly twofold higher risk of shingles within 60 days of COVID-19 vaccination. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_61 | Evidence_Covid_B2.0_41 | COVID-19 Vaccine Causes Shingles | F | null | a large case-control study from Israelopens in a new tab or window that involved nearly 900,000 vaccinated individuals and an equal number of comparators reported a 43% higher risk of herpes zoster after vaccination | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_61 | Evidence_Covid_B2.0_42 | COVID-19 Vaccine Causes Shingles | F | null | "Our study included a racially and ethnically heterogenous cohort compared with the studies conducted in Israel and may therefore better represent post-vaccination herpes zoster event risk in diverse populations," according to the researchers. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_62 | Evidence_Covid_B2.0_43 | COVID-19 Vaccine Causes Shingles | T | null | For example, an international matched cohort studyopens in a new tab or window involving more than 1 million vaccinated individuals detected a nearly twofold higher risk of shingles within 60 days of COVID-19 vaccination. | covid vaccine_4090 | Study found increase in shingles after vaccination. |
B_2.0 | Claims_Covid_B2.0_62 | Evidence_Covid_B2.0_44 | COVID-19 Vaccine Causes Shingles | T | null | a large case-control study from Israelopens in a new tab or window that involved nearly 900,000 vaccinated individuals and an equal number of comparators reported a 43% higher risk of herpes zoster after vaccination | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_62 | Evidence_Covid_B2.0_45 | COVID-19 Vaccine Causes Shingles | T | null | "Our study included a racially and ethnically heterogenous cohort compared with the studies conducted in Israel and may therefore better represent post-vaccination herpes zoster event risk in diverse populations," according to the researchers. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_62 | Evidence_Covid_B2.0_46 | COVID-19 Vaccine Causes Shingles | T | null | No association was detected between COVID-19 vaccination and herpes zoster infection in a database study involving more than 2 million individuals in the U.S. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_62 | Evidence_Covid_B2.0_47 | COVID-19 Vaccine Causes Shingles | T | null | Using a self-controlled risk interval (SCRI) analysis, the risk of herpes zoster in the month after receiving a dose of COVID-19 vaccine was no different when compared with a control period 60 to 90 days following an individuals' last dose (incidence rate ratio [IRR] 0.91, 95% CI 0.82-1.01, P=0.08), reported Nisha Acharya, MD, MS, of the University of California San Francisco, and colleagues. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_62 | Evidence_Covid_B2.0_48 | COVID-19 Vaccine Causes Shingles | T | null | "There was no increase in risk of herpes zoster after COVID-19 vaccination when individuals were stratified by age, immunocompromised status, or type of vaccine administered," the group wrote in JAMA Network Openopens in a new tab or window. | covid vaccine_4090 | null |
B_2.0 | Claims_Covid_B2.0_63 | Evidence_Covid_B2.0_49 | XBB Covid strain is vaccine resistant | T | null | US health chiefs revealed last month they were 'monitoring' a new Covid variant that is feared to be the 'most vaccine-resistant yet'. | covid vaccine_4091 | XBB Omicron variant is the most vaccine resistant yet. |
B_2.0 | Claims_Covid_B2.0_63 | Evidence_Covid_B2.0_50 | XBB Covid strain is vaccine resistant | T | null | XBB is another spin-off of the Omicron variant and has been blamed for Singapore's sudden surge in infections. | covid vaccine_4091 | null |
B_2.0 | Claims_Covid_B2.0_63 | Evidence_Covid_B2.0_51 | XBB Covid strain is vaccine resistant | T | null | The alarm has been sounded by experts including Dr Raj Rajnarayanan at the New York Institute of Technology who said it was the 'most immune evasive yet'. | covid vaccine_4091 | null |
B_2.0 | Claims_Covid_B2.0_63 | Evidence_Covid_B2.0_52 | XBB Covid strain is vaccine resistant | T | null | Scientists warn that it is likely better at dodging immunity than others based on lab tests of its grand-father BA.2.75. | covid vaccine_4091 | null |
B_2.0 | Claims_Covid_B2.0_63 | Evidence_Covid_B2.0_53 | XBB Covid strain is vaccine resistant | T | null | Modelling by the Fred Hutchinson Cancer Center's Bloom Lab in Seattle, Washington, also warned it was likely better at immune escape. | covid vaccine_4091 | null |
B_2.0 | Claims_Covid_B2.0_63 | Evidence_Covid_B2.0_54 | XBB Covid strain is vaccine resistant | T | null | XBB is another spin-off of the Omicron variant and was blamed for Singapore's sudden surge in infections. | covid vaccine_4091 | null |
B_2.0 | Claims_Covid_B2.0_64 | Evidence_Covid_B2.0_55 | Breastfeeding protects against COVID-19 | T | null | Several studies have reported the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human milk after lactating women have received two doses of messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines. | covid vaccine_4093 | Antibodies against covid found in breast milk after at least two vaccines |
B_2.0 | Claims_Covid_B2.0_64 | Evidence_Covid_B2.0_56 | Breastfeeding protects against COVID-19 | T | null | More specifically, IgG and IgA against the SARS-CoV-2 spike protein have been identified in human milk following vaccination and infection. | covid vaccine_4093 | null |
B_2.0 | Claims_Covid_B2.0_64 | Evidence_Covid_B2.0_57 | Breastfeeding protects against COVID-19 | T | null | Further information is needed on the duration and potency of antibody responses in breast milk beyond the second vaccination and the effect of hybrid immunity obtained by breakthrough infections during the Omicron era. | covid vaccine_4093 | null |
B_2.0 | Claims_Covid_B2.0_64 | Evidence_Covid_B2.0_58 | Breastfeeding protects against COVID-19 | T | null | Nevertheless, data on the symptomology and immune protection produced following infection and vaccination are limited for breastfeeding infants and lactating individuals. | covid vaccine_4093 | null |
B_2.0 | Claims_Covid_B2.0_64 | Evidence_Covid_B2.0_59 | Breastfeeding protects against COVID-19 | T | null | More information is therefore needed to determine the protection against COVID-19 during the vulnerable months of infancy, the level of antibody transfer to infants and the persistence of anti-SARS-CoV-2 antibodies in milk post-vaccination. | covid vaccine_4093 | null |
B_2.0 | Claims_Covid_B2.0_64 | Evidence_Covid_B2.0_60 | Breastfeeding protects against COVID-19 | T | null | A new The Lancet preprint* study assesses anti-SARS-CoV-2 antibody levels in breast milk obtained from lactating individuals following two or three COVID-19 vaccine doses and following breakthrough infections in vaccinated mothers. | covid vaccine_4093 | null |
B_2.0 | Claims_Covid_B2.0_65 | Evidence_Covid_B2.0_61 | Immunocompromised Patients with Blood Cancer Benefit from covid-19 vaccine | T | null | “There was a great need to protect these patients, particularly through vaccination,” Dr. Hazenberg says. “At the same time, it was unclear if patients would be able to build up sufficient protection through vaccination since they are immunocompromised. There is not much data on the effect of vaccination as it pertains to the most immunocompromised patients. Therefore, there was a great need to investigate the immunogenicity of COVID-19 vaccinations in patients with hematologic malignancies.” | covid vaccine_4096 | 3 doses of vaccine in blood cancer patients is as effective as 2 doses in healthy people |
B_2.0 | Claims_Covid_B2.0_65 | Evidence_Covid_B2.0_62 | Immunocompromised Patients with Blood Cancer Benefit from third covid-19 vaccine | T | null | For a study published in JAMA Oncology, Dr. Hazenberg and colleagues investigated whether a third mRNA-1273 vaccination is linked with increased neutralization of antibody concentrations in patients with hematologic cancers who are immunocompromised compared with levels obtained in healthy controls after the standard two-dose mRNA vaccination schedule. | covid vaccine_4096 | null |
B_2.0 | Claims_Covid_B2.0_65 | Evidence_Covid_B2.0_63 | Immunocompromised Patients with Blood Cancer Benefit from covid-19 vaccine | T | null | “Antibody concentrations obtained from our patients after the standard two-dose vaccination were lower than in the healthy population, but nevertheless, much higher than expected,” | covid vaccine_4096 | null |
B_2.0 | Claims_Covid_B2.0_65 | Evidence_Covid_B2.0_64 | Immunocompromised Patients with Blood Cancer Benefit from covid-19 vaccine | T | null | When three-dose schedule antibody concentrations are reached in immunocompromised patients, they are comparable to those of healthy controls after two doses, she says, adding that vaccination should not be deferred in patients with hematologic conditions during a pandemic, or in patients receiving immunochemotherapy or transplantation. | covid vaccine_4096 | null |
B_2.0 | Claims_Covid_B2.0_65 | Evidence_Covid_B2.0_65 | Immunocompromised Patients with Blood Cancer Benefit from covid-19 vaccine | T | null | “In patients receiving B cell-depleting therapies, vaccination can be effective, partly because other immune cells, such as T cells, are activated.” | covid vaccine_4096 | null |
B_2.0 | Claims_Covid_B2.0_65 | Evidence_Covid_B2.0_66 | Immunocompromised Patients with Blood Cancer Benefit from covid-19 vaccine | T | null | A relatively small group of patients had extremely poor antibody responses, the study team observed. “It’s important to protect these individuals from infection by wearing masks and utilizing other infection prevention measures,” Dr. Hazenberg says. | covid vaccine_4096 | null |
B_2.0 | Claims_Covid_B2.0_66 | Evidence_Covid_B2.0_67 | Covid vaccine has minimal impact on virus transmission | T | null | Butler said the Australian Technical Advisory Group on Immunisations (ATAGI) had recommended against a fifth dose, or third booster, after evidence from Singapore's recent wave showed that severe illness and death were rare among the vaccinated and that a fifth shot had minimal impact on virus transmission. | covid vaccine_4097 | The boosters are not really providing any prolonged protection against transmission |
B_2.0 | Claims_Covid_B2.0_66 | Evidence_Covid_B2.0_68 | Covid vaccine has minimal impact on virus transmission | T | null | We need to improve the quality of the vaccines, the durability, the ability to stop transmission | covid vaccine_4185 | null |
B_2.0 | Claims_Covid_B2.0_66 | Evidence_Covid_B2.0_69 | Covid vaccine has minimal impact on virus transmission | T | null | The boosters are not really providing any prolonged protection against transmission | covid vaccine_4185 | null |
B_2.0 | Claims_Covid_B2.0_66 | Evidence_Covid_B2.0_70 | Covid vaccine has minimal impact on virus transmission | T | null | You could have one now and by mid-January you'd be getting very little protection against transmissions whereas, interestingly, natural infection is much more effective. | covid vaccine_4185 | null |
B_2.0 | Claims_Covid_B2.0_66 | Evidence_Covid_B2.0_71 | Covid vaccine has minimal impact on virus transmission | T | null | Biden and his top advisers have pointed to the overwhelming body of scientific research showing the vaccines are safe and effective at stopping the transmission of the coronavirus | covid vaccine_4267 | null |
B_2.0 | Claims_Covid_B2.0_66 | Evidence_Covid_B2.0_72 | Covid vaccine has minimal impact on virus transmission | T | null | a virus that has become even more transmissible as it has mutated | covid vaccine_4266 | null |
B_2.0 | Claims_Covid_B2.0_67 | Evidence_Covid_B2.0_73 | Australia recommends against fifth vaccine dose | T | null | Australian health authorities have recommended against getting a fifth COVID-19 vaccine shot | covid vaccine_4097 | Australian health authorities have recommended against getting a fifth COVID-19 vaccine shot |
B_2.0 | Claims_Covid_B2.0_67 | Evidence_Covid_B2.0_74 | Australia recommends against fifth vaccine dose | T | null | Butler said the Australian Technical Advisory Group on Immunisations (ATAGI) had recommended against a fifth dose | covid vaccine_4097 | null |
B_2.0 | Claims_Covid_B2.0_67 | Evidence_Covid_B2.0_75 | Australia recommends against fifth vaccine dose | T | null | ATAGI has considered international evidence as well as the local data around vaccination numbers, as well as case numbers in the pandemic and decided not to recommend a fifth dose, said Butler. | covid vaccine_4097 | null |
B_2.0 | Claims_Covid_B2.0_67 | Evidence_Covid_B2.0_76 | Australia recommends against fifth vaccine dose | T | null | fifth vaccine dose has not been recommended by the Australian Technical Advisory Group of Immunisation [Atagi] | covid vaccine_4105 | null |